Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)		0	250
Convertible Series F Preferred Stock [Member]
Antidilutive Securities (in shares)	[1]	51,357	184,820
Series F Preferred Warrants [Member]
Antidilutive Securities (in shares)	[2]	2,784,921	2,932,486
Common Stock Warrants [Member]
Antidilutive Securities (in shares)		2,272,203	2,071,855

[1] Calculation assumes the conversion of the stated value and accrued dividends of the Series F Preferred Stock into Common Stock at the current exercise price of $11.168.

[2] Calculation assumes the exercise of the Series F Preferred Warrants for cash into Series F Preferred Stock and subsequent conversion of the Series F Preferred Stock into Common Stock at the Floor Price of $11.168.